Argenx's Efgartigimod Becomes First Phase 3 Therapy To Show Statistically Significant, Clinically Meaningful Improvement In IMNM, A Subtype With No Approved Treatment

argenx SE

argenx SE

ARGX

0.00
  • Study met primary endpoint of mean Total Improvement Score (TIS) at Week 52 in the combined study population of IMNM and DM patients (p=0.0011)
  • Patient improvements observed early and sustained throughout study; consistent treatment effect across IMNM and DM
  • First Phase 3 study to show statistically significant and clinically meaningful improvements in disease activity in IMNM, a subtype with no approved therapy
  • argenx to host a conference call on August 17th at 2:30 PM CET/ 8:30 AM ET
This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.